LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

Ankura™ Aortic Stent Graft System Obtained Official Registration Approval from the China NMPA

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 8 February 2025, the Ankura™ Aortic Stent Graft System (the "**Product**") jointly developed by Professor Shu Chang of Fuwai Hospital, Chinese Academy of Medical Sciences, and the Group, obtained official registration approval from the China National Medical Products Administration ("**NMPA**"). The Product is the first aortic stent graft system approved by NMPA to be explicitly applicable to the chimney technique, providing a new treatment option for patients with lesions involving the aortic arch, which is simple to operate, safe and effective, and has a wide range of anatomical adaptations.

The Product consists of Ankura™ Pro Aortic Stent Graft System (the "**Ankura™ Pro**") and Longuette™ Aortic Branch Stent Graft System (the "**Longuette™ Skirt Stent**"). The Ankura™ Pro adopts ePTFE film coating and offers a variety of tapers from 0 to 10 for patients to meet different clinical needs. The Longuette™ Skirt Stent adopts a dual-layer stent design with an external skirt layer that can fill the gutter between the branch stent and the aortic stent once released. It is expected that the Longuette™ Skirt Stent can prevent the incidence of endoleak and reduce the risk of complications. According to the three-year follow-up result, the incidence of the endoleak is only 3.36%, far lower than that of traditional chimney technique (10.7%~16.4%). The inner layer is made of high-density nickel titanium alloy

skeleton, and the proximal reinforcement segment that provides strong radial support to prevent from being compressed by aortic stent, ensuring long-term patency of the branch vessel. The patency rate of the branch vessel during the one-year follow-up after surgery was 97.87%, which was higher than that of the traditional chimney technique (93%). The Product can be implanted easily, and it is also safe and efficient with an immediate technical success rate of 99.33% and a one-year post-operative success rate of 95.77% for aortic dissection treatment.

The Product possesses independent intellectual property rights and a number of international patents. It is expected to provide a complete, safe and effective endovascular repair solution for patients with lesions involving the aortic arch, which is completely interventional with the expected benefits of less trauma and simpler operation.

The Product is the first approved product under the Company's comprehensive solution for the reconstruction of aortic arch branches. As the commercialization process continues to progress, the Company will provide an integrated solution for endovascular aortic arch reconstruction that is more flexible, comprehensive, safer and more effective, and simple to operate. Furthermore, in collaboration with industry experts, the Company will advance the research, development, and launch of additional device products that are urgently needed in clinical practice, thereby driving the Group's development in the field of medical devices and benefiting a wide range of patients.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 12 February 2025

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. RUAN Xingmei being executive directors; Mr. JIANG Feng being non-executive director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive directors.